Healthcare Market Desk

Pulmonary Arterial Hypertension (PAH) Market Value, Volume, Company Share Analysis and Forecast 2019-2026

Press release   •   Sep 17, 2019 10:41 EDT

The report analyzes and forecasts the pulmonary arterial hypertension (PAH) market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. Increasing prevalence of Pulmonary Arterial Hypertension (PAH) and government support for the development of orphan drugs are fueling the growth.

The cases of PAH are rising in the range of 100,000 to 200,000 per year. However, in the past few years, the occurrence of this disorder has intensified due to the risk factors such as alcohol/tobacco consumption, HIV, sedentary lifestyle, smoking, and other idiopathic conditions. Presence of a large geriatric population, with lower levels of immunity and prone to PAH and associated diseases, is a high impact-rendering driver for the PAH market. Though the beginning age for PAH is 45 years, it is often observed to occur in the population over 60 years of age.

Get Free Report Sample Copy for More Understanding@ https://www.visionresearchreports.com/report/sample/28879

Government initiatives, such as the Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 are also anticipated to support market growth. These are the two most vital acts that promote the ethical usage and distribution of orphan drugs. Development of orphan drugs is promoted by the National Organization of Rare Disorders and have a smaller market share.

The report comprises a detailed value chain analysis, which provides a comprehensive view of the global pulmonary arterial hypertension (PAH) market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view of the pulmonary arterial hypertension (PAH) market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The report provides size (in terms of volume and value) of pulmonary arterial hypertension (PAH) market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.

The report has analyzed few of the leading companies in the market. Actelion Pharmaceuticals Ltd., Gilead Sciences Inc., Pfizer Inc., GlaxoSmithKline Plc., Novartis International AG, Bayer HealthCare, and United Therapeutics Corp are few prominent companies in the global pulmonary arterial hypertension market.

Request to Buy This Premium Report From here@ https://www.visionresearchreports.com/report/cart/28879

Segments Covered in the Report:

Drug Class Outlook (Revenue, USD Million, 2015 - 2026)

Prostacyclin & Prostacyclin Analogs

SGC Stimulators

ERA

PDE-5

Regional Outlook (Revenue, USD Million, 2015 - 2026)

North America

Europe

Asia Pacific

Latin America

Middle East and Africa (MEA)

Reasons to Purchase this Report:

- Estimates 2019-2026 pulmonary arterial hypertension (PAH) market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Research Methodology:

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.

Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.

Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.

The study objectives of this report are:

  • To analyze and study the global pulmonary arterial hypertension (PAH) capacity, production, value, consumption, status (2014-2018) and forecast (2019-2026);
  • Focuses on the key pulmonary arterial hypertension (PAH) manufacturers, to study the capacity, production, value, market share and development plans in future.
  • Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
  • To define, describe and forecast the market by type, application and region.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends and factors driving or inhibiting the market growth.
  • To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  • To strategically profile the key players and comprehensively analyze their growth strategies.

Request to Buy This Premium Report From here@ https://www.visionresearchreports.com/report/cart/28879

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Drug
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.2 Volume Price Analysis (Model 2)
1.6.2.1 Approach 2: Volume Price Analysis
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective - 1:
1.10.2 Objective - 2:
1.10.3 Objective - 3:
1.10.4 Objective - 4:
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 Pulmonary Arterial Hypertension Market: Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Product Pipeline Analysis, By Stage
3.3.1 Registration Phase
3.4 User Perspective Analysis
3.4.1 Consumer Behavior Analysis
3.4.2 Market Influencer Analysis
3.5 List Of Key End-Users, By Region / By Product / By Country
3.6 Regulatory Framework
3.6.1 Reimbursement framework
3.6.1.1 Therapy cost
3.6.1.2 Therapy monitoring cost
3.6.1.3 Average Selling Price
3.6.2 Standards & Compliances
3.7 Market Variable Analysis
3.7.1 Market Driver Analysis
3.7.1.1 Incidents of Pulmonary Arterial Hypertension (PAH)
3.7.1.2 Growing Geriatric Population
3.7.1.3 Government Support for Development of Orphan Drugs
3.7.2 Market Restraint Analysis
3.7.2.1 Patent Expiration Of Key Molecules
3.7.3 Industry Challenges
3.8 Pulmonary Arterial Hypertension Market: Analysis Tools
3.8.1 Porter’s Five Forces Analysis
3.8.1.1 Supplier Power: Low
3.8.1.2 Buyer Power: moderate
3.8.1.3 Substitution Threat: moderate
3.8.1.4 Threat from new entrant: moderate
3.8.1.5 Competitive rivalry: high
3.8.2 Pestel Analysis
3.8.3 Major Deals & Strategic Alliances Analysis
3.8.4 Market Entry Strategies
Chapter 4 Pulmonary Arterial Hypertension Market: Drug Class Segment Analysis
4.1 Pulmonary Arterial Hypertension Market: Definition & Scope
4.2 Pulmonary Arterial Hypertension: Market Share Analysis, 2018 & 2026
4.3 Prostacyclin and Prostacyclin Analogs
4.3.1 Prostacyclin and Prostacyclin Analogs market, 2015 - 2026 (USD Million)
4.4 Soluble Guanylate Cyclase (Sgc) Stimulators
4.4.1 Soluble Guanylate Cyclase (Sgc) Stimulators Market, 2015 - 2026 (USD Million)
4.5 Endothelin Receptor Antagonists (ERAs)
4.5.1 Endothelin Receptor Antagonists (Eras) Market, 2015 - 2026 (USD Million)
4.6 Phosphodiesterase 5 (Pde-5)
4.6.1 Phosphodiesterase 5 (Pde-5) Market, 2015 - 2026 (USD Million)
Chapter 5 Pulmonary Arterial Hypertension Market: Regional Analysis
5.1 Pulmonary Arterial Hypertension Market: Definition & Scope
5.2 Regional Market Snapshot
5.3 Regional Market Share and Leading Players, 2018
5.3.1 North America
5.3.2 Europe
5.3.3 Asia Pacific
5.3.4 Latin America
5.3.5 Middle East & Africa
5.4 Pulmonary Arterial Hypertension Market: Market Share Analysis, 2018 & 2026
5.5 North America
5.5.1 North America Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.5.2 U.S.
5.5.2.1 U.S. Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.5.3 Canada
5.5.3.1 Canada Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.6 Europe
5.6.1 Europe Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.6.2 U.K.
5.6.2.1 U.K. Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.6.3 Germany
5.6.3.1 Germany Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.6.4 France
5.6.4.1 France Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.6.5 Italy
5.6.5.1 Italy Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.6.6 Spain
5.6.6.1 Spain Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.7 Asia Pacific
5.7.1 Asia Pacific Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.7.2 Japan
5.7.2.1 Japan Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.7.3 China
5.7.3.1 China Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.7.4 Australia
5.7.4.1 Australia Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.7.5 South Korea
5.7.5.1 South Korea Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.8 Latin America
5.8.1 Latin America Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.8.2 Brazil
5.8.2.1 Brazil Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.8.3 Mexico
5.8.3.1 Mexico Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.8.4 Argentina
5.8.4.1 Argentina Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.9 MEA
5.9.1 MEA Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.9.2 South Africa
5.9.2.1 South Africa Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.9.3 Saudi Arabia
5.9.3.1 Saudi Arabia Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
5.9.4 UAE
5.9.4.1 UAE Pulmonary Arterial Hypertension Market, 2015 - 2026 (USD Million)
Chapter 6 Company Profiles
6.1 Company Profiles
6.1.1 Actelion Pharmaceuticals, Ltd.
6.1.1.1 Company overview
6.1.1.2 Financial performance
6.1.1.3 Product benchmarking
6.1.1.4 Strategic initiatives
6.1.2 Gilead Sciences, Inc.
6.1.2.1 Company overview
6.1.2.2 Financial PErformance
6.1.2.3 Product benchmarking
6.1.2.4 Strategic initiatives
6.1.3 United Therapeutics Corporation
6.1.3.1 Company overview
6.1.3.2 Financial performance
6.1.3.3 PAH Global Sale
6.1.3.4 Product benchmarking
6.1.3.5 Strategic initiatives
6.1.4 Novartis International AG
6.1.4.1 Company overview
6.1.4.2 Financial Performance
6.1.4.3 Product benchmarking
6.1.4.4 Strategic initiatives
6.1.5 GlaxoSmithKline Plc. (GSK)
6.1.5.1 Company overview
6.1.5.2 Financial performance
6.1.5.3 Product benchmarking
6.1.6 Pfizer, Inc.
6.1.6.1 Company overview
6.1.6.2 Product benchmarking
6.1.7 Dong-A ST Co., Ltd.
6.1.7.1 Company overview
6.1.7.2 Financial performance
6.1.7.3 Product benchmarking
6.1.7.4 Strategic initiatives
6.1.8 Merck Sharp & Dohme Corp.
6.1.8.1 Company overview
6.1.8.2 Finanical Performance
6.1.8.3 Product benchmarking
6.1.8.4 Strategic initiatives
6.1.9 Bayer HealthCare
6.1.9.1 Company overview
6.1.9.2 Financial Performance
6.1.9.3 Product benchmarking
6.1.9.4 Strategic initiatives
6.1.10 Arena Pharmaceuticals
6.1.10.1 Company overview
6.1.10.2 Financial performance
6.1.10.3 Product benchmarking
Chapter 7 KOL Commentary
7.1 Key Insights
7.2 KOL Views
Chapter 8 Recommendations

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbrevations
Table 3 Product pipeline analysis
Table 4 Pipeline Analysis for the PAH Agents
Table 5 Monthly therapy cost for PAH agents
Table 6 Payer specific per patient per year monitoring cost by medication class
Table 7 Average selling prices for approved PAH agents in the U.S.
Table 8 Global Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
Table 9 Global Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 10 North America Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
Table 11 North America Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 12 U.S. Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 13 Canada Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 14 Europe Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
Table 15 Europe Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 16 U.K. Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 17 Germany Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 18 Spain Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 19 Italy Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 20 France Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 21 RoE Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 22 Asia Pacific Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
Table 23 Asia Pacific Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 24 Japan Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 25 China Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 26 India Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 27 Australia Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 28 South Korea Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 29 RoAPAC Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 30 Latin America Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
Table 31 Latin America Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 32 Brazil Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 33 Mexico Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 34 Argentina Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 35 RoLA Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 36 MEA Pulmonary Arterial Hypertension Market, by Region, 2015 - 2026 (USD Million)
Table 37 MEA Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 38 South Africa Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 39 Saudi Arabia Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 40 UAE Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)
Table 41 RoMEA Pulmonary Arterial Hypertension Market, by Drug Class, 2015 - 2026 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity Flow Analysis
Fig. 9 Volume Price Analysis
Fig. 10 Pulmonary arterial hypertension market snapshot (2018)
Fig. 11 Pulmonary arterial hypertension market segmentation
Fig. 12 Pulmonary arterial hypertension market: Strategy framework
Fig. 13 Market trends and outlook
Fig. 14 Parent market outlook
Fig. 15 Related/ancillary market outlook
Fig. 16 Penetration & growth prospect mapping
Fig. 17 Market driver relevance analysis (Current & future impact)
Fig. 18 Global prevalence of PAH
Fig. 19 Global geriatric population, 2014 - 2024 (Million)
Fig. 20 Market restraint relevance analysis (Current & future impact)
Fig. 21 Patent term expiry of the key PAH brand
Fig. 22 Porter’s five forces analysis
Fig. 23 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 24 Pulmonary arterial hypertension market drug class outlook: Segment dashboard
Fig. 25 Pulmonary arterial hypertension market: Drug class movement analysis
Fig. 26 Prostacyclin pathway
Fig. 27 Prostacyclin and prostacyclin analogs market, 2015 - 2026 (USD Million)
Fig. 28 Nitric oxide pathway
Fig. 29 Soluble guanylate cyclase (SGC) stimulators market, 2015 - 2026 (USD Million)
Fig. 30 Endothelial pathway
Fig. 31 Endothelin receptor antagonists (eras) market, 2015 - 2026 (USD Million)
Fig. 32 Nitric oxide pathway market, 2015 - 2026 (USD Million)
Fig. 33 Phosphodiesterase 5 (PDE-5) market, 2015 - 2026 (USD Million)
Fig. 34 Regional market place: Key takeaways
Fig. 35 Pulmonary Arterial Hypertension Market: Definition & Scope
Fig. 36 Regional Market Snapshot (Figures in USD Million, 2018)
Fig. 37 Regional Market Share, 2018 (USD Million)
Fig. 38 Regional outlook, 2018 & 2026
Fig. 39 North America market, 2015 - 2026 (USD Million)
Fig. 40 U.S. market, 2015 - 2026 (USD Million)
Fig. 41 Canada market, 2015 - 2026 (USD Million)
Fig. 42 Europe market, 2015 - 2026 (USD Million)
Fig. 43 U.K. market, 2015 - 2026 (USD Million)
Fig. 44 Germany market, 2015 - 2026 (USD Million)
Fig. 45 France market, 2015 - 2026 (USD Million)
Fig. 46 Italy market, 2015 - 2026 (USD Million)
Fig. 47 Spain market, 2015 - 2026 (USD Million)
Fig. 48 Asia Pacific market, 2015 - 2026 (USD Million)
Fig. 49 Japan market, 2015 - 2026 (USD Million)
Fig. 50 China market, 2015 - 2026 (USD Million)
Fig. 51 Australia market, 2015 - 2026 (USD Million)
Fig. 52 South Korea market, 2015 - 2026 (USD Million)
Fig. 53 Latin America market, 2015 - 2026 (USD Million)
Fig. 54 Brazil market, 2015 - 2026 (USD Million)
Fig. 55 Mexico market, 2015 - 2026 (USD Million)
Fig. 56 Argentina market, 2015 - 2026 (USD Million)
Fig. 57 MEA market, 2015 - 2026 (USD Million)
Fig. 58 South Africa market, 2015 - 2026 (USD Million)
Fig. 59 Saudi Arabia market, 2015 - 2026 (USD Million)
Fig. 60 UAE market, 2015 - 2026 (USD Million)

Request to Buy This Premium Report From here@ https://www.visionresearchreports.com/report/cart/28879